Myriad Genetics (NASDAQ:MYGN) Releases FY25 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.07-0.11 for the period, compared to the consensus estimate of $0.15. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $879.47 million. Myriad Genetics also updated its Q4 guidance to $0.03-0.04 EPS.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Morgan Stanley lowered their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research note on Monday, November 18th. UBS Group assumed coverage on shares of Myriad Genetics in a research report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price objective for the company. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Thursday, January 9th. Leerink Partnrs downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Finally, Leerink Partners cut Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $30.00 to $21.00 in a research report on Monday, December 9th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $24.27.

Myriad Genetics Stock Performance

MYGN opened at $13.68 on Wednesday. Myriad Genetics has a twelve month low of $12.87 and a twelve month high of $29.30. The stock has a market cap of $1.25 billion, a PE ratio of -10.52 and a beta of 1.89. The business’s 50 day moving average is $15.05 and its 200-day moving average is $22.17. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.